IMVT vs RNAC
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. RNAC: Cartesian Therapeutics is pioneering mRNA-engineered cell therapies designed to provide durable autoimmune disease treatment without the toxicity associated with conventional DNA-based CAR-T therapies.
Side-by-side fundamentals
| Metric | IMVT | RNAC | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $30.26 | $6.82 | |
| Market cap | $6.3B | $206M | |
| Net margin FY2025, SEC XBRL | n/a | -32575.5% | |
| Operating margin FY2025, SEC XBRL | n/a | -35851.3% | |
| ROE FY2026, SEC XBRL | -59.3% | n/a | |
| ROA | -52.8% | -44.0% | RNAC higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -94.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -84.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.20 | 1.99 | |
| 1-year return as of 2026-10-08 close | +88.2% | -33.3% | IMVT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.